Company: MBIO
Filing Date: 2025-12-23
Form Type: 8-K
Source: 0001104659-25-124189
Chunk: 2

Company: MUSTANG BIO, INC.
Filing Date: 2025-12-23
Form: 8-K
Item: Item 5.07
Chunk 2
---
; and (iii) the parties agreed that, in the event that Fred Hutch, during the three-year period following execution of the Termination and Release Agreement, grants any third party a license under the CD20 patents or other intellectual property that had been licensed to the Company under the CD20 License Agreement, then Fred Hutch will pay to the Company at least 10% of all consideration received by Fred Hutch from such third party under such licensing arrangement (with an additional obligation to negotiate in good faith for a potentially greater percentage share).

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibits are filed as part of this report:

  Exhibit No.      Description                                                                 
 ───────────────────────────────────────────────────────────────────────────────────────────────
         10.1      Amendment No. 3 to the Mustang Bio, Inc. 2019 Employee Stock Purchase Plan  
         10.2      Fourth Amendment to the Mustang Bio, Inc., 2016 Incentive Plan              
          104      Cover Page Interactive Data File (formatted as Inline XBRL)